China SFDA Expands Drug-Illegality Whistleblower Program, Ups Rewards
This article was originally published in PharmAsia News
China's State FDA announced a system to reward whistleblowers with a bit more than $48,000 if they report illegal activities related to drug and food safety risks.
You may also be interested in...
Phase I data presented at ASCO for ALLO-501 offer proof of concept for the CD19 allogeneic CAR-T and a companion drug, ALLO-647, for lymphodepletion.
Dispatches from a world turned upside down covering a possible US government investigation into BARDA contracting practices and Medicare Part D plans waiving cost sharing for COVID-19 treatments.
The US FDA requests several manufacturers recall extended-release metformin based on studies confirming a higher NDMA impurity threshhold; previous testing found no significant risks.